Invention Grant
- Patent Title: WT1 antigen peptide conjugate vaccine
-
Application No.: US14706772Application Date: 2015-05-07
-
Publication No.: US09248173B2Publication Date: 2016-02-02
- Inventor: Chiang Jia Li , Hitoshi Ban , Yukihiro Nishio , Masashi Goto , Toshio Nishihara , Yosuke Takanashi
- Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD. , INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
- Applicant Address: JP Osaka-shi JP Suita-shi
- Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.,INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
- Current Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.,INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
- Current Assignee Address: JP Osaka-shi JP Suita-shi
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2013-072173 20130329; JP2013-158383 20130731
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K38/16 ; A61K39/00 ; C07K7/06 ; C07K7/08 ; C07K14/00 ; C07K14/47 ; A61K47/48

Abstract:
A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Public/Granted literature
- US20150238587A1 WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE Public/Granted day:2015-08-27
Information query
IPC分类: